Podcast: How to bridge diversity gaps in cancer clinical trials
Luther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities
May 17, 2021
Diversity in cancer clinical trials is essential to show if potential treatments are safe and work well for people of all different communities. That’s why it’s crucial to break down barriers and increase participation in cancer clinical trials among historically underrepresented communities.
In this podcast, Luther Clark, Merck’s deputy chief patient officer, speaks with the Lazarex Cancer Foundation’s founder and CEO, Dana Dornsife, and its health equity and diversity coordinator, Marya Shegog, about the work they’ve been doing — and the work that still needs to be done — to foster health equity through cancer clinical trials.